Its been a long time since the S&P 500 has had a perfect week. By perfect, we mean five consecutive days stretching from Monday through Friday with the index setting a new record high each day. The last one was recorded in 1998, according to Howard Silverblatt, senior index analyst for S&P Dow Jones Indices.
Are we about to break that dry spell? Today, the S&P 500 closed at a fresh record high for the fourth consecutive day, something that hasnt happened since November 2014. Up 11 points, or 0.5%, the benchmark ended at 2,163, spurred on by better-than-expected earnings from J.P. Morgan Chase & Co. (JPM).
Elsewhere, the DJIA added 134 points, or 0.7%, to 18,506.4, for its third record finish in a row. The Nasdaq, climbed 28 points, or 0.6%, to end at 5,034.06, reaching its highest level for 2016.
Investors shrugged off a surprise decision by the Bank of England to stand pat on interest rates. Meanwhile, J.P. Morgan delivered a strong second quarter earnings report, which lifted the shares 1.5% and pulled other big banks along for the ride. The Financial Select Sector SPDR ETF (XLF) rose 0.9% to close at %23.56.
Top Stocks To Invest In 2018: Aethlon Medical, Inc.(AEMD)
- [By Monica Gerson]
General Mills, Inc. (NYSE: GIS) is expected to report its quarterly earnings at $0.60 per share on revenue of $3.86 billion.
Pier 1 Imports Inc (NYSE: PIR) is projected to post a quarterly loss at $0.05 per share on revenue of $420.05 million.
Acuity Brands, Inc. (NYSE: AYI) is estimated to report its quarterly earnings at $2.03 per share on revenue of $847.79 million.
Monsanto Company (NYSE: MON) is projected to report its quarterly earnings at $2.40 per share on revenue of $4.49 billion.
Worthington Industries, Inc. (NYSE: WOR) is expected to report its quarterly earnings at $0.64 per share on revenue of $692.48 million.
Progress Software Corporation (NASDAQ: PRGS) is projected to post its quarterly earnings at $0.29 per share on revenue of $94.64 million.
UniFirst Corp (NYSE: UNF) is estimated to report its quarterly earnings at $1.34 per share on revenue of $366.28 million.
Exfo Inc (NASDAQ: EXFO) is expected to post its quarterly earnings at $0.06 per share on revenue of $60.87 million.
OMNOVA Solutions Inc. (NYSE: OMN) is projected to report its quarterly earnings at $0.14 per share on revenue of $205.40 million.
8Point3 Energy Partners LP (NASDAQ: CAFD) is estimated to post a quarterly loss at $0.01 per share on revenue of $11.60 million.
Park Electrochemical Corp. (NYSE: PKE) is expected to report its quarterly earnings at $0.22 per share on revenue of $35.30 million.
Xplore Technologies Corp. (NASDAQ: XPLR) is projected to post its quarterly earnings at $0.01 per share on revenue of $24.00 million.
Investors Real Estate Trust (NYSE: IRET) is expected to post its quarterly earnings at $0.14 per share on revenue of $56.87 million.
Tel-Instrument Electronics Corp. (NYSE: TIK) is estimated to post earnings for the latest quarter.
Aethlon Medical, Inc. (NASDAQ: AEMD) is expected to post a quarterly loss at $0.20 per share.
Ossen Innovation Co Ltd (ADR) (NASDAQ: OSN) is projected to post ea
Top Stocks To Invest In 2018: One Horizon Group, Inc.(OHGI)
- [By Lisa Levin] Gainers
Aimmune Therapeutics Inc (NASDAQ: AIMT) shares jumped 35 percent to $34.64 in response to failed DBVT peanut allergy trial.
Exactech, Inc. (NASDAQ: EXAC) shares surged 30.9 percent to $41.88 after the company agreed to be acquired by TPG Capital for $42 per share in cash.
Dextera Surgical Inc (NASDAQ: DXTR) shares climbed 27.6 percent to $0.238 after surging 40.48 percent on Friday.
Petmed Express Inc (NASDAQ: PETS) jumped 21.8 percent to $44.73 as the company reported better-than-expected Q2 results.
SenesTech Inc (NASDAQ: SNES) shares surged 21.7 percent to $1.95 after the company disclosed that Univar will be marketing and selling ContraPest.
Yulong Eco-Materials Ltd (NASDAQ: YECO) shares gained 18.3 percent to $0.560.
One Horizon Group Inc (NASDAQ: OHGI) shares rose 18 percent to $1.18.
Atossa Genetics Inc (NASDAQ: ATOS) shares climbed 18 percent to $0.566. Atossa Genetics is schedule to host a conference call to announce preliminary results from Phase 1 study of oral Endoxifen on October 25, 2017.
ReneSola Ltd. (ADR) (NYSE: SOL) shares rose 15.3 percent to $2.72
Renren Inc (NYSE: RENN) shares gained 11.9 percent to $10.71 after gaining 2.68 percent on Friday.
Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares rose 11.8 percent to $12.59. KalVista Pharma 13D filing from Longwood Fund showed registration for an 8.7 percent stake.
Xunlei Ltd (NASDAQ: XNET) shares gained 9.4 percent to $7.20 after surging 25.33 percent on Friday.
VF Corp (NYSE: VFC) shares surged 7.1 percent to $71.09 after the company reported upbeat earnings for its third quarter and raised its FY2017 guidance.
CAI International Inc (NYSE: CAI) rose 6.6 percent to $39.70. Cowen & Co. upgraded CAI from Market Perform to Outperform.
Agenus Inc (NASDAQ: AGEN) shares gained 5.7 percent to $4.58 as the company disclosed that GSK's shingle vaccine received FDA approval.
Deltic Timber Corp (NYSE: DEL) shares climbed 5.6 percent to $94.11
Top Stocks To Invest In 2018: Edwards Lifesciences Corporation(EW)
- [By Ben Levisohn]
Edwards Lifesciences (EW) soared to the top of the S&P 500 today after the medical-device company beat earnings and revenue forecasts, and raised its full-year guidance.
Edwards Lifesciencesgained 11% to 109.33, while the S&P 500 dipped 0.1% to 2,387.45.
Mogran Stanley’s David Lewis andScott Wang contend that that Edwards Lifesciences is “back on track.” They explain:
US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achievable expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.
Edwards Lifesciences’ market capitalization rose to $23.1 billion today from $20.9 billion yesterday.
- [By Chris Lange]
The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was Edwards Lifesciences Corp. (NYSE: EW) which jumped about 10% to $108.91. The stocks 52-week range is $81.12 to $1221.75. Volume was roughly 7.3million which is above the daily average of around 2.2 million shares.
- [By Lisa Levin]
Edwards Lifesciences Corp (NYSE: EW) announced plans to buy Valtech Cardio for $340 million in cash and stock. The company also announced a $1 billion buyback plan.
Epizyme Inc (NASDAQ: EPZM) disclosed that it has received Fast Track designation for tazemetostat.
Athene Holding Ltd. (NYSE: ATH) reported that it has priced its 23.8 million share IPO between $38 per share and $42 per share.
Lannett Company, Inc. (NYSE: LCI) reported the approval for its Metaxalone Tablets USP, 800 mg.
- [By Ben Levisohn]
Shares of Edwards Lifesciences (EW) jumped to the top of the S&P 500 today after the medical-device maker offered its 2017 guidance this morning at its investor day.
Shares of Edwards Lifesciences gained 6.7% to $89.31 today, while the S&P 500 rose 0.2% to 2,246.19.
Wells Fargo’sLarry Biegelsen offers his take on Edwards Lifesciences’ guidance:
Edwards Lifesciences Corporation (EW-$83.73; Outperform) provided its 2017 outlook this morning (12/8) ahead of its investor meeting today. As expected, the company highlighted its robust pipeline which should drive strong growth for years to come. However, the company now expects Q4 16 revenue to come in at the low end of the guidance range due to currency and weakness in surgical heart valves. The 2017 guidance was generally strong on the top and bottom line, with both bracketing consensus.
For 2017, EW expects sales of $3.0-3.4B and 10-14% underlying growth. This compares to consensus of $3.3B and 12.3% underlying growth (were at 12.6%)… For 2017 EPS, EW expects $3.30-3.45 which includes $0.10 dilution from the Valtech deal (something we highlighted in our preview) and $0.08-0.10 benefit from the accounting change for stock based compensation. Backing these two items out implies guidance of about $3.30-3.45 which compares to consensus of $3.40 and our estimate of $3.41…
As expected, the pipeline updates were highly positive. While the initial reaction to the Q4 guidance will likely be negative, we are highly confident that the strong 2017 guidance and robust pipeline update will be the main takeaways from the meeting today.
No negativity here: Edwards Lifesciences’ market capitalization rose to $19.1 billion today from $17.9 billion yesterday. It reported net income of $495 million on sales of $2.5 billion in 2015.